Compare AMST & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | ASBP |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.8M |
| IPO Year | 2020 | N/A |
| Metric | AMST | ASBP |
|---|---|---|
| Price | $1.00 | $6.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 86.4K | ★ 95.9K |
| Earning Date | 05-13-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,459.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $0.05 |
| 52 Week High | $4.78 | $7.05 |
| Indicator | AMST | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.06 | 55.84 |
| Support Level | $0.88 | $4.29 |
| Resistance Level | $2.12 | $6.88 |
| Average True Range (ATR) | 0.10 | 0.63 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 10.26 | 83.48 |
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery.